Recommended Products
biological source
rabbit
Quality Level
100
500
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
SP76, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (371R-14)
vial of 0.5 mL concentrate (371R-15)
bottle of 1.0 mL predilute (371R-17)
vial of 1.0 mL concentrate (371R-16)
bottle of 7.0 mL predilute (371R-18)
manufacturer/tradename
Cell Marque™
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200
isotype
IgG
control
squamous epithelium
shipped in
wet ice
storage temp.
2-8°C
visualization
nuclear
Gene Information
human ... SOX2(6657)
Related Categories
General description
It has been reported that anti-SOX-2 antibody recognizes lung squamous cell carcinoma (LSCC). A recent study has demonstrated that extensive anti-SOX-2 staining was seen in over 90% of LSCC and largely paralleled p63 expression. Extensive anti-SOX-2 staining was seen in 21% of lung adenocarcinomas (LACA), including cases that were anti-p63-negative or only anti-p63 focally-positive. However, another recent study showed only 4.5% of LACA is positive for anti-SOX-2 expression. In a study by Sholl et al, 29% of LACA cases exhibited at least focal p63 expression. Combined p63 and SOX-2 expression was seen in 94% of LSCC and 12% of LACA with a statistically significant difference (P<0.0001) versus p63 alone. This study also showed that anti-CK5/6 had a good sensitivity but poor specificity for LSCC. Combined anti-CK5/6 and anti-p63 positivity was seen in 93% of LSCC and 24% of LACA. Anti-CK5/6+/anti-p63+/anti- SOX-2+ was detected in 93% of LSCC and only 9% of LACA. These results indicate that the sensitivity of anti-p63 is equally high but its specificity is similarly variable; it was seen at least focally in close to 30% of LACA. When used together, anti-p63+/anti-SOX-2+ applied to the same tumor cell population is >90% specific for LSCC. Anti-SOX-2 produced moderate-to-intense staining in all 50 cases of embryonal carcinoma components. The only other component that showed reactivity was the primitive neuroectodermal component in 11 of 14 (79%) of immature teratomas. In each of these positive staining foci, the staining varied from moderate-to-strong. Yolk sac tumor, seminoma, mature teratoma, choriocarcinoma, and IGCNU were uniformly negative, as were all the non-neoplastic parenchymal and stromal structures.
Quality
 IVD |  IVD |  IVD |  RUO |
Linkage
SOX-2 Positive Control Slides, Product No. 371S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
control
Product No.
Description
Pricing
Regulatory Information
监管及禁止进口产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Koji Tsuta et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(7), 1190-1199 (2011-05-31)
Recent clinical trials revealed that accurate histologic typing of non-small cell lung cancer, especially squamous cell carcinoma (SCC), is essential. We analyzed 10 antibodies expression in 150 SCC cases (53 well-, 51 moderately, and 46 poorly differentiated cases) and 159
Lynette M Sholl et al.
Applied immunohistochemistry & molecular morphology : AIMM, 18(1), 55-61 (2009-08-08)
Sox2 is a transcription factor that regulates embryonic stem cell pluripotency and drives commitment of airway precursor cells to basal-type and neuroendocrine cells in the developing lung. In cancer, Sox2 has been associated with a "stemness" phenotype that predicts for
Anuradha Gopalan et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 22(8), 1066-1074 (2009-04-28)
Stem cell markers, OCT3/4, and more recently SOX2 and growth differentiation factor 3 (GDF3), have been reported to be expressed variably in germ cell tumors. We investigated the immunohistochemical expression of these markers in different testicular germ cell tumors, and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service